Parent Project Muscular Dystrophy (PPMD), in collaboration with Duchenne advocacy partners Best Day Ever Foundation, Coalition Duchenne, CureDuchenne, Jett Foundation, Kindness Over Muscular Dystrophy, Inc., Little Hercules Foundation, Muscular Dystrophy Association, Muscular Dystrophy Family Foundation, and Team Joseph, hosted a community webinar on July 7, 2026, focused on how our community can engage in the upcoming FDA Advisory Committee (Ad Comm) meeting for Deramiocel on July 29, 2026.

This Ad Comm represents a critical moment for individuals and families living with Duchenne. The FDA will be evaluating Deramiocel, and the voices of the Duchenne community play a vital role in helping regulators understand the real-world impact of this disease and the urgent need for new treatment options. During this webinar, we walk through what to expect from the Ad Comm, why it matters, and the different ways you can get involved. This includes opportunities to submit public comments, request to join a speaking group during the Open Public Hearing, and help elevate the patient and caregiver perspective throughout the process.

Whether you are new to advocacy or have participated in past FDA meetings, this discussion provides clear, actionable guidance to help you make your voice heard. Watch the recording to learn how you can be part of this important moment for the Duchenne community.

Learn more in our blogs here and here.

Our written comment guide can be found here.

If you are interested in requesting an OPH speaking opportunity, please complete our interest form as soon as possible.